Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Filament Health Corp N.FH

Alternate Symbol(s):  FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral... see more

Recent & Breaking News (NEO:FH)

FILAMENT HEALTH ANNOUNCES ANNUAL GENERAL MEETING VOTING RESULTS

Canada NewsWire June 28, 2022

FILAMENT HEALTH ANNOUNCES PATIENT DOSING THROUGH HEALTH CANADA SPECIAL ACCESS PROGRAM

Canada NewsWire June 16, 2022

FILAMENT HEALTH CULTIVATES 70TH PSYCHEDELIC MUSHROOM VARIETY AND ANNOUNCES ANNUAL GENERAL MEETING

Canada NewsWire June 10, 2022

Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

Canada NewsWire June 9, 2022

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

GlobeNewswire May 31, 2022

FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS

Canada NewsWire May 17, 2022

The StockTalk Cannabis Report: April 29, 2022

Dave Jackson April 29, 2022

Filament Health announces 4th patent issuance

Stockhouse Editorial April 28, 2022

FILAMENT HEALTH ANNOUNCES FOURTH PATENT ISSUANCE

Canada NewsWire April 27, 2022

Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products

GlobeNewswire April 19, 2022

FILAMENT HEALTH AND PSYENCE ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR NATURAL PSILOCYBIN PRODUCTS

Canada NewsWire April 19, 2022

The StockTalk Cannabis Report: April 15, 2022

Dave Jackson April 15, 2022

FILAMENT HEALTH IS ISSUED PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE

Canada NewsWire April 13, 2022

FILAMENT HEALTH ANNOUNCES PRE-IND MEETING WITH UNITED STATES FOOD AND DRUG ADMINISTRATION

Canada NewsWire April 12, 2022

FILAMENT HEALTH TO PARTICIPATE IN PROMINENT PSYCHEDELIC INVESTOR CONFERENCES IN APRIL 2022

Canada NewsWire April 7, 2022

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire March 31, 2022

FILAMENT HEALTH ANNOUNCES SECOND PATENT ISSUANCE

Canada NewsWire March 23, 2022

Filament Health to Participate in the 34th Annual Roth Conference

Canada NewsWire March 8, 2022

Filament Health (NEO:FH) and ATMA Journey Centers announce licensing agreement

John Ballem  February 23, 2022

Filament Health and ATMA Journey Centers Announce Licensing Agreement

PR Newswire February 23, 2022